This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Email citation

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Case Reports

. 2007 Dec;18(12):2045-6.

doi: 10.1093/annonc/mdm515.

Reversible liver toxicity with adjuvant trastuzumab for localized breast cancer

A Muñoz, S Carrera, J Ferreiro, A Ruiz de Lobera, J M Mañé, G López-Vivanco

PMID: 18083694
DOI: 10.1093/annonc/mdm515

Free article

Case Reports

Reversible liver toxicity with adjuvant trastuzumab for localized breast cancer

A Muñoz et al. Ann Oncol. 2007 Dec.

Free article

. 2007 Dec;18(12):2045-6.

doi: 10.1093/annonc/mdm515.

Authors

A Muñoz, S Carrera, J Ferreiro, A Ruiz de Lobera, J M Mañé, G López-Vivanco

PMID: 18083694
DOI: 10.1093/annonc/mdm515

No abstract available

PubMed Disclaimer

Similar articles

[Breast cancer: adjuvant therapy with trastuzumab: herceptin adjuvant (HERA) Trial Study, B-31- and N9831-Study].
Mallmann P. Mallmann P. Internist (Berl). 2006 Nov;47(11):1183-5. doi: 10.1007/s00108-006-1720-x. Internist (Berl). 2006. PMID: 17048017 German. No abstract available.
Trastuzumab--mechanism of action and use in clinical practice.
Hudis CA. Hudis CA. N Engl J Med. 2007 Jul 5;357(1):39-51. doi: 10.1056/NEJMra043186. N Engl J Med. 2007. PMID: 17611206 Review. No abstract available.
Spotlight on trastuzumab as adjuvant treatment in human epidermal growth factor receptor 2 (HER2)-positive early breast cancer.
Garnock-Jones KP, Keating GM, Scott LJ. Garnock-Jones KP, et al. BioDrugs. 2010 Jun;24(3):207-9. doi: 10.2165/11204680-000000000-00000. BioDrugs. 2010. PMID: 20462285 No abstract available.
Trastuzumab in breast cancer.
Gilbert SG. Gilbert SG. N Engl J Med. 2006 Feb 9;354(6):640-4; author reply 640-4. doi: 10.1056/NEJMc053177. N Engl J Med. 2006. PMID: 16467555 No abstract available.
Ongoing adjuvant trials with trastuzumab in breast cancer.
Tan AR, Swain SM. Tan AR, et al. Semin Oncol. 2003 Oct;30(5 Suppl 16):54-64. doi: 10.1053/j.seminoncol.2003.08.008. Semin Oncol. 2003. PMID: 14613027 Review.

See all similar articles

Cited by

Trastuzumab-induced hepatotoxicity: a case report.
Vucicevic D, Carey EJ, Karlin NJ. Vucicevic D, et al. Breast Care (Basel). 2013 May;8(2):146-8. doi: 10.1159/000346844. Breast Care (Basel). 2013. PMID: 24419371 Free PMC article.
Hepatotoxicity induced by trastuzumab used for breast cancer adjuvant therapy: a case report.
Ishizuna K, Ninomiya J, Ogawa T, Tsuji E. Ishizuna K, et al. J Med Case Rep. 2014 Dec 10;8:417. doi: 10.1186/1752-1947-8-417. J Med Case Rep. 2014. PMID: 25491149 Free PMC article.
A phase I dose-escalation study of a biosimilar trastuzumab in Chinese metastasis breast cancer patients.
Zhou X, Yu J, Wang W, Song G, Wang X, Ren J, Di L, Wang X. Zhou X, et al. Springerplus. 2015 Dec 22;4:803. doi: 10.1186/s40064-015-1603-5. eCollection 2015. Springerplus. 2015. PMID: 26702392 Free PMC article.

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- Elsevier Science
- Ovid Technologies, Inc.
Medical
- MedlinePlus Health Information